Clinical and Pharmacologic Profile of a Subcutaneous Lecanemab Formulation
Subcutaneous lecanemab has low-risk for immunogenicity. Lecanemab, administered subcutaneously, has a safety, tolerability, and pharmacodynamic profile that favorably compares to the approved 10mg/kg biweekly intravenous dose, and autoinjector administration provides greater patient convenience.
Authors
- T. Doherty (ORCID: https://orcid.org/0000-0002-4183-5595)
- Shobha Dhadda (ORCID: https://orcid.org/0000-0002-7290-7168)
- Steven M. Hersch (ORCID: https://orcid.org/0000-0001-5948-6672)
- Michelle Gee
- Lynn D. Kramer
- Penner Natasha
- Michael C. Irizarry
- Anna Patten
- Larisa Reyderman
Institutions
- Eisai (United Kingdom) (GB)
- Eisai (United States) (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_104691
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00